ELF score is elevated in patients with recent arthroplasty: a cross-sectional study.
- 1Renown Health, 745 W. Moana Lane, Suite 375, Reno, NV, 89509, USA. [email protected].
- 2Renown Health, 745 W. Moana Lane, Suite 375, Reno, NV, 89509, USA.
- 3University of Nevada, Reno School of Public Health, Reno, NV, USA.
Abstract
Background
The Enhanced Liver Fibrosis (ELF) test is a non-invasive blood test for liver fibrosis, with elevated scores indicating referral to hepatology. However, components of ELF can also be elevated due to extra-hepatic fibrosis after arthroplasty (AP), potentially increasing false positive results. In this study, we investigate whether time since AP is associated with the risk that ELF exceeds clinical thresholds of 9.8 or 11.3.Methods
ELF tests were administered to 5,707 Renown Health patients as part of routine clinical care (N = 1,099) or as part of participating in the Helix Research Network Sub-Study MNASH (HRNSM; N = 4,608). For ELF-tested patients with prior AP, generalized additive logistic regression models were used to assess the association of ELF and ELF components with time since most recent AP. Relative risks (RRs) for elevated values were adjusted for age, sex, HRNSM participation, and ELF testing date.Results
Among ELF-tested patients, we identified 488 patients with prior AP. The RRs of ELF > 9.8 were 1.49 (95% confidence interval [CI]: 1.30, 1.71) and 1.39 (CI: 1.18, 1.63) for patients with AP within 0.5 years prior and AP between 0.5 and 1 years prior, respectively, compared to patients with AP > 2 years prior. Similarly, the RR of ELF > 11.3 was 4.52 (CI: 2.26, 9.02) for patients with AP within 0.5 years. Of the ELF components, procollagen III N-terminal propeptide (PIIINP) contributed the most to elevated ELF scores following AP, with RR 2.32 (CI: 1.93, 2.79) of PIIINP > 9.9 ng/mL for patients with AP within 0.5 years.Conclusions
Compared to patients with AP further in the past, patients with recent AP were significantly more likely to have elevated ELF scores. If extra-hepatic causes are verified, our results indicate that the specificity of ELF for liver fibrosis may be reduced following AP.
Related
- Total Hip Arthroplasty Is Associated With Lower 90-Day Inpatient Readmission Than Hemiarthroplasty for Femoral Neck Fracture in Patients Aged 65-75 Years: A Propensity Score-Matched Nationwide Readmissions Database Study
- Inpatient outcomes after primary total knee arthroplasty in patients receiving chronic dialysis: A nationwide propensity score-matched analysis
- GRIT Score Does Not Correlate With QuickDASH Scores in Patients Who Undergo Carpometacarpal Arthroplasty for Thumb Carpometacarpal Arthritis
- Development and Validation of a Machine Learning-Based Model for Elevated Depressive Symptom Risk in COPD Patients: A Multi-Cohort Cross-Sectional Study.
- Association of the triglyceride-glucose index with elevated somatic symptoms: a cross-sectional study in patients with hypertension
BibTeX
@article{kiser2026score,
title = {{ELF score is elevated in patients with recent arthroplasty: a cross-sectional study.}},
author = {Daniel Kiser and Gai Elhanan and Karen Schlauch and Robert Read and Joseph J Grzymski},
journal = {BMC gastroenterology},
year = {2026},
month = aug,
doi = {10.1186/s12876-026-05188-4},
url = {https://europepmc.org/article/MED/42968004},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - ELF score is elevated in patients with recent arthroplasty: a cross-sectional study.
AU - Daniel Kiser
AU - Gai Elhanan
AU - Karen Schlauch
AU - Robert Read
AU - Joseph J Grzymski
PY - 2026
DA - 2026/08/04
JO - BMC gastroenterology
DO - 10.1186/s12876-026-05188-4
UR - https://europepmc.org/article/MED/42968004
AB - Background The Enhanced Liver Fibrosis (ELF) test is a non-invasive blood test for liver fibrosis, with elevated scores indicating referral to hepatology. However, components of ELF can also be elevated due to extra-hepatic fibrosis after arthroplasty (AP), potentially increasing false positive results. In this study, we investigate whether time since AP is associated with the risk that ELF exceeds clinical thresholds of 9.8 or 11.3.Methods ELF tests were administered to 5,707 Renown Health patients as part of routine clinical care (N = 1,099) or as part of participating in the Helix Research Network Sub-Study MNASH (HRNSM; N = 4,608). For ELF-tested patients with prior AP, generalized additive logistic regression models were used to assess the association of ELF and ELF components with time since most recent AP. Relative risks (RRs) for elevated values were adjusted for age, sex, HRNSM participation, and ELF testing date.Results Among ELF-tested patients, we identified 488 patients with prior AP. The RRs of ELF > 9.8 were 1.49 (95% confidence interval [CI]: 1.30, 1.71) and 1.39 (CI: 1.18, 1.63) for patients with AP within 0.5 years prior and AP between 0.5 and 1 years prior, respectively, compared to patients with AP > 2 years prior. Similarly, the RR of ELF > 11.3 was 4.52 (CI: 2.26, 9.02) for patients with AP within 0.5 years. Of the ELF components, procollagen III N-terminal propeptide (PIIINP) contributed the most to elevated ELF scores following AP, with RR 2.32 (CI: 1.93, 2.79) of PIIINP > 9.9 ng/mL for patients with AP within 0.5 years.Conclusions Compared to patients with AP further in the past, patients with recent AP were significantly more likely to have elevated ELF scores. If extra-hepatic causes are verified, our results indicate that the specificity of ELF for liver fibrosis may be reduced following AP.
SN - 1471-230X
ER -